A share price of Transmedics Group Inc [TMDX] is currently trading at $143.69, up 1.22%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TMDX shares have gain 4.45% over the last week, with a monthly amount glided 16.68%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Transmedics Group Inc [NASDAQ: TMDX] stock has seen the most recent analyst activity on October 23, 2025, when Needham upgraded its rating to a Buy but kept the price target unchanged to $148 for it. Previously, Jefferies started tracking the stock with Buy rating on October 13, 2025, and set its price target to $145. On September 16, 2025, Evercore ISI initiated with a Outperform rating and assigned a price target of $155 on the stock. Stifel started tracking the stock assigning a Hold rating and suggested a price target of $115 on September 04, 2025. JP Morgan downgraded its rating to a Neutral and reduced its price target to $75 on December 17, 2024. Needham downgraded its rating to Hold for this stock on November 22, 2024. In a note dated October 29, 2024, Oppenheimer reiterated an Outperform rating on this stock and revised its target price from $200 to $125.
Transmedics Group Inc experienced fluctuations in its stock price throughout the past year between $55.00 and $156.00. Currently, Wall Street analysts expect the stock to reach $148.17 within the next 12 months. Transmedics Group Inc [NASDAQ: TMDX] shares were valued at $143.69 at the most recent close of the market. An investor can expect a potential return of 3.12% based on the average TMDX price forecast.
Analyzing the TMDX fundamentals
Trailing Twelve Months sales for Transmedics Group Inc [NASDAQ:TMDX] were 566.35M which represents 32.24% growth. Gross Profit Margin for this corporation currently stands at 0.6% with Operating Profit Margin at 0.17%, Pretax Profit Margin comes in at 0.16%, and Net Profit Margin reading is 0.16%. To continue investigating profitability, this company’s Return on Assets is posted at 0.1, Equity is 0.31 and Total Capital is 0.11. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.46.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Transmedics Group Inc [NASDAQ:TMDX] is 7.69. Also, the Quick Ratio is 7.13, while the Cash Ratio stands at 5.85. Considering the valuation of this stock, the price to sales ratio is 8.67, the price to book ratio is 13.81 and price to earnings (TTM) ratio is 58.04.
Transactions by insiders
Recent insider trading involved Weill David, Director, that happened on Dec 03 ’25 when 5000.0 shares were sold. Chief Financial Officer, Hernandez Gerardo completed a deal on Dec 04 ’25 to sell 920.0 shares. Meanwhile, Director DAVID WEILL bought 5000.0 shares on Dec 03 ’25.
